Search clinical trials for: Bombesin (68Ga) labeled (BAY86-7548)

Total 54 results

Life Molecular Imaging SA

Completed

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

Diagnostic Imaging

Switzerland, Finland, Germany
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
Andrei Iagaru
General Electric

Completed

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Prostate Cancer

United States
Life Molecular Imaging SA

Terminated

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Prostate Cancer

Austria, Finland
Andrei Iagaru

Completed

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Prostate Adenocarcinoma

United States
Andrei Iagaru
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Prostate Cancer

United States
Stanford University
National Cancer Institute (NCI)

Completed

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Prostate Carcinoma

United States
Shanghai General Hospital, Shanghai Jiao Tong University...
NanoMab Technology (UK) Limited

Completed

68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage

Prostate Cancer

China
Affiliated Hospital of Jiangnan University

Recruiting

68Ga-labeled NY108 PET Imaging in Patients

Prostatic Cancer

China
Xijing Hospital

Not yet recruiting

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

HER2-positive Breast Cancer and Gastric Cancer
Medical University Innsbruck
Novartis

Completed

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

Neuroendocrine Tumors

Austria
Peter MacCallum Cancer Centre, Australia

Recruiting

Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions (SPECIFIC)

Invasive Fungal Infections

Australia
Bayer

Terminated

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers

Diagnostic Imaging

Switzerland, Germany
Thomas Hope
Clovis Oncology, Inc.

Recruiting

Imaging of Solid Tumors Using FAP-2286

Metastatic Cancer | Solid Tumors, Adult

United States
Andrei Iagaru
General Electric

Completed

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Prostate Cancer

United States
St Vincent's Hospital, Sydney
Clarity Pharmaceuticals Ltd

Completed

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) (BOP)

Prostate Cancer

Australia
Mayo Clinic

Withdrawn

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Mayo Clinic

Recruiting

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8

United States
Jonsson Comprehensive Cancer Center

Completed

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than Fifty

United States
Jonsson Comprehensive Cancer Center

Completed

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy (PSMA SRT)

Recurrent Prostate Carcinoma

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Jonsson Comprehensive Cancer Center

Terminated

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Jonsson Comprehensive Cancer Center

Terminated

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Jonsson Comprehensive Cancer Center
Society of Nuclear Medecine and Molecular Imaging

Recruiting

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Breast Carcinoma | Gastric Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Colon Carcinoma | Esophageal Carcinoma | Kidney Carcinoma | Pancreatic Carcinoma | Uterine Corpus Cancer | Solid Neoplasm

United States
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8
Xijing Hospital

Completed

68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

Lung Cancer | Lung Tuberculosis
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI); United States Department of Defense

Recruiting

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer

Hepatocellular Carcinoma

United States
UNC Lineberger Comprehensive Cancer Center

Withdrawn

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
University of California, San Francisco

Completed

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (PSMA BCR)

Prostate Cancer

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Telix International...

Active, not recruiting

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Prostate Adenocarcinoma

United States
Mayo Clinic

Completed

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

Hepatocellular Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular Carcinoma

United States
University of California, San Francisco

Terminated

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

Thyroid Gland Carcinoma

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Not yet recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
University of California, San Francisco
Radiological Society of North America

Completed

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
Thomas Hope
Gateway for Cancer Research; Prostate Cancer Foundation; Conquer Cancer Foundation

Active, not recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic

Not yet recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery (PSMA vs AXUMIN)

Recurrent Prostate Carcinoma

United States
Andrei Iagaru

Completed

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | PSA Failure

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States

Search clinical trials for: Bombesin (68Ga) labeled (BAY86-7548)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations